A human plasma-derived tripeptide with high copper affinity, studied for collagen remodeling, skin repair, and gene expression modulation.
~1 - 2 hours (free tripeptide)
TGF-beta Receptor
C14H24CuN6O4
Used topically in dermatological formulations (1-2%) and investigated via subcutaneous injection.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for GHK-Cu: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C14H24CuN6O4
Gly-His-Lys (chelated with Cu2+)
Isolated by Dr. Loren Pickart in 1973, GHK-Cu is a naturally occurring peptide whose plasma levels decline significantly with age. Research demonstrates broad epigenetic actions, altering the expression of over 4,000 human genes toward a youthful, restorative baseline, including genes involved in DNA repair and antioxidant defense.
Stimulates synthesis of collagen Types I, III, and IV, decorin, and elastin. Modulates matrix metalloproteinases (MMPs) and TIMPs to rebuild healthy extracellular matrix while reducing inflammatory cytokine release (TNF-alpha, IL-6).
Peer-reviewed publications, clinical trials, and preclinical research investigating GHK-Cu.
Comprehensive review and gene-array profiling detailing how GHK-Cu resets gene expression in human fibroblasts toward a younger phenotype and accelerates cutaneous wound closure.
Documented literature dosing intervals and published clinical trial protocols.
Biological delivery routes and standardized laboratory reconstitution principles.
Used topically in dermatological formulations (1-2%) and investigated via subcutaneous injection.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
